Amgen Inc.

Massachusetts Institute of Technology

Novartis Ag

Xencor, Inc.

Novartis Pharma Ag

Neeraj Jagdish Agrawal

Zhulun Wang

Ian Nevin Foltz

Kevin Graham

Gunasekaran Kannan

Darren L Bates

Christopher Mohr

Christopher Murawsky

Kenneth William Walker

Agnes Eva Hamburger

Derek Evan Piper

Cen Xu

Bernhardt Levy Trout

Xiaoshan Min

Murielle M Veniant-Ellison

Donghui Shi

Junming Yie

David J Lloyd

Jinghong Wang

Shu-yin Ho

Li Erran Li

Ai Ching Lim

Marc A Gavin

Dong Xia

Bernhard Helk

Kathy Manchulenko

Da Ren

Marissa Mock

Gregory L Moore

Randal Robert Ketchem

Jeffrey T McGrew

Brandon C P Clavette

Renee Komorowski

Glenn N Sivits, Jr

Pavel V Bondarenko

Laura Sekirov

Joon Hoi Huh

Shunsuke Takenaka

Dina N Alcorn

Khaled M K Z Ali

Christy Ann Thomson

Cyr Clovis Chua De Imus

Kelly Ann Berry

Eric Alan Butz

Andrew Nichols

Riki Stevenson

Christopher James Sloey

Sekhar Kanapuram

Jennitte LeAnn Stevens

Richard Smith

Benjamin M Alba

Dante Romanini

Olivier Nolan-Stevaux

Pavan K Ghattyvenkatakrishna

Oliver Thiel

Curtiss Paul Schneider

Stephen Smith

Li Li

John K Kawooya

Dina A Fomina Yadlin

Victoria Wagner

Ray Lieh Yoon Low

Alex W Jacobitz

Cong Li

Daren Bates

Randal Robert Ketchum

Noelia Blanco Talavan

Ian Foltz

Kristine M Daris

Huong Thi Ngoc Le

Shunseke Takenaka

Khaled MKZ Ali

Trent P Munro

Marc Alain Gavin

The present invention is directed to a CH3-containing molecule comprising (a) a first polypeptide comprising a CH3 domain and a negatively charged domain comprising consecutive negatively charged amino acid residues; and (b) a second polypeptide comprising a CH3 domain and a positively charged domain comprising consecutive positively charged amino acid residues. Also provided are methods for conjugating synthetic molecules to a multi-specific antigen binding molecule.

Bispecific antibodies with cleavable C-terminal charge-paired tags

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)

Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamate-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.

N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides

The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.

Low-viscosity antigen binding proteins and methods of making them

Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

Interleukin-2 muteins for the expansion of T-regulatory cells

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof

Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.

Interleukin-21 mutein/ anti-PD-1 antibody conjugates

The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.

Anti-STEAP1 antigen-binding protein

Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.

Anti-PD-1 antibodies and methods of treatment

Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof

The present invention concerns a method for preparing antigen binding proteins with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Provided herein are high-throughput methods for identifying a candidate antibody based on viscosity of the candiate antibody.

Computer-implemented methods of determining protein viscosity

PAC1 antibodies and uses thereof

Growing community of inventors

Waltham, MA, United States of America

Neeraj Jagdish Agrawal